![Min Zhong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Xiayang Qiu | M | - |
QILU Regor Therapeutics, Inc.
Regor Therapeutics Group
![]() Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | 6 years |
Wen Ge Zhong | M | - |
QILU Regor Therapeutics, Inc.
| 6 years |
Ling Xu | F | - |
Regor Therapeutics Group
![]() Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | 3 years |
Xiao Tian Zhu | M | - |
QILU Regor Therapeutics, Inc.
| 6 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
China | 3 | 75.00% |
United States | 2 | 50.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Min Zhong
- Personal Network